Skip to main content

Table 3 Relative expression levels of KRAS (A) and HRAS (B) mRNA in tissue of NSCLC patients, compared to clinicopathological and demographical features

From: Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings

  Relative KRAS expression level in tissue
  N Median Minimum Maximum p-value
A
All cases 35 0.8917 0.0631 12.9178  
Cigarette No 13 0.7730 0.0631 7.0357 1.0000
Yes 22 0.9600 0.0941 12.9178
Sexr Women 7 0.7730 0.0941 8.2563 0.8528
Men 28 0.9586 0.0631 12.9178
Age <= 67 18 0.3768 0.0941 3.5158 0.0361
>  67 17 1.2411 0.0631 12.9178
Histological type of cancer Squamous 21 0.8917 0.0941 12.9178 0.5333
Glandular 14 0.8652 0.0631 7.0357
TNM stage IA1 and/or IA2 and/or IB 16 0.9589 0.0631 12.9178 0.9868
II A and/or II B and/or IIIA 19 0.7534 0.1109 8.2563
Grade of histological malignancy [G] G1 and/or G2 27 0.9575 0.0631 12.9178 0.5169
G3 8 0.5918 0.1109 6.4671
Chemotherapy No 22 0.8045 0.0631 12.9178 0.1887
Yes 13 0.9597 0.2825 7.0357
B
All cases 35 0.9779 0.0544 24.1938  
Cigarette No 13 0.9779 0.0737 11.5889 0.7491
Yes 22 0.8728 0.0544 24.1938
Sex Women 7 0.2131 0.0737 6.7824 0.3325
Men 28 1.0848 0.0544 24.1938
Age <= 67 18 0.3621 0.0544 5.3788 0.0892
>  67 17 1.2699 0.0653 24.1938
Histological type of cancer Squamous 21 0.4161 0.0544 24.1938 0.0489
Glandular 14 1.6400 0.0797 11.5889
TNM stage IA1 and/or IA2 and/or IB 16 0.6167 0.0737 24.1938 0.6311
II A and/or II B and/or IIIA 19 1.0854 0.0544 11.5889
Grade of histological malignancy [G] G1 and/or G2 27 0.6614 0.0737 24.1938 0.7683
G3 8 1.2824 0.0544 11.5889
Chemotherapy No 22 0.4941 0.0544 24.1938 0.0978
Yes 13 1.3379 0.1702 11.5889